newsfilter
← Latest News
Business Wire·

IONTAS Collaboration With F-star Enters Oncology Phase 1 Clinical Trial

IONTAS Limited (IONTAS), a leader in the discovery and optimization of fully human antibodies, today announces that F-star Therapeutics, Inc. (NASDAQ:FSTX), has dosed the first patients in a Phase 1 clinical trial, with FS222, a CD137/PD-L1 bispecific a